Abstract
The term metabolic syndrome (MeS) refers to a cluster of associated symptoms composed of impaired fasting glucose, abdominal obesity, hypertension, and dyslipidemia. MeS is associated with an increased risk of cardiovascular and diabetes-associated morbidity and mortality. The increased amount of visceral fat together with a chronic inflammatory state predisposes to the development of arteriosclerosis. Furthermore, insulin resistance (IR) and dyslipidemia are associated with fatty liver disease. In addition, MeS is linked to non-cardiovascular diseases such as cancer as well as psychiatric or endocrine disorders. Here, we discuss the clinical impact of MeS in cardiovascular and non-cardiovascular diseases to highlight the importance of prevention, early diagnosis, and multifactorial treatment of high-risk individuals.
| Original language | English |
|---|---|
| Journal | Visceral Medicine |
| Volume | 32 |
| Issue number | 5 |
| Pages (from-to) | 336-341 |
| Number of pages | 6 |
| ISSN | 2297-4725 |
| DOIs | |
| Publication status | Published - 01.01.2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)
Fingerprint
Dive into the research topics of 'Clinical Scenario of the Metabolic Syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver